2.02
+0.06(+3.06%)
Currency In USD
| Previous Close | 1.96 |
| Open | 2 |
| Day High | 2.09 |
| Day Low | 1.93 |
| 52-Week High | 7.68 |
| 52-Week Low | 1 |
| Volume | 676,767 |
| Average Volume | 2M |
| Market Cap | 62.72M |
| PE | -1.03 |
| EPS | -1.97 |
| Moving Average 50 Days | 2.03 |
| Moving Average 200 Days | 1.74 |
| Change | 0.06 |
If you invested $1000 in Immuneering Corporation (IMRX) since IPO date, it would be worth $114.84 as of January 19, 2025 at a share price of $2.02. Whereas If you bought $1000 worth of Immuneering Corporation (IMRX) shares 3 years ago, it would be worth $163.96 as of January 19, 2025 at a share price of $2.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
GlobeNewswire Inc.
Jan 13, 2025 1:00 PM GMT
- Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer - - Overall Response Rate (ORR) of 50%; historic benchmark of 32% for FOLFIRINOX alone - - Ne
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms
GlobeNewswire Inc.
Jan 07, 2025 12:00 PM GMT
- Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients show favorable overall response rate (ORR = 43%) and disease control rate (DCR = 86%); planning for pivotal trial und
Immuneering Launches Pancreatic Cancer Advisory Board
GlobeNewswire Inc.
Dec 19, 2024 1:00 PM GMT
- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and second-line pancreatic cancer for IMM-1-104 - C